The gold standard treatment of neovascular, or wet, AMD is primarily based on VEGF targeting, despite the critical role of other cytokines and growth factors such as MCP-1, TNF α and basic fibroblast growth factor (bFGF) in AMD pathology [4]. This evidence concerns the gene FGF2 and age-related macular degeneration.